Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
Haowen Tang, Wenwen Zhang, Junning Cao, Yinbiao Cao, Xinyu Bi, Haitao Zhao, Ze Zhang, Zhe Liu, Tao Wan, Ren Lang, Wenbing Sun, Shunda Du, Yongping Yang, Yinying Lu, Daobing Zeng, Jushan Wu, Binwei Duan, Dongdong Lin, Fei Li, Qinghua Meng, Jun Zhou, Baocai Xing, Xiaodong Tian, Jiye Zhu, Jie Gao, Chunyi Hao, Zhiqiang Wang, Feng Duan, Zhijun Wang, Maoqiang Wang, Bin Liang, Yongwei Chen, Yinzhe Xu, Kai Li, Chengang Li, Minggen Hu, Zhao-Hai Wang, Shouwang Cai, Wenbin Ji, Nian-Xin Xia, Wenheng Zheng, Hongguang Wang, Li Gong, Ziman Zhu, Zhiyong Huang, Wanguang Zhang, Kaishan Tao, Jun Liang, Keming Zhang, Chaoliu Dai, Jiangtao Li, Qiu Qiu, Yuan Guo, Liqun Wu, Weibao Ding, Zhenyu Zhu, Wanqing Gu, Jingyu Cao, Zusen Wang, Lantian Tian, Huiguo Ding, Guangming Li, Yongyi Zeng, Kui Wang, Ning Yang, Haosheng Jin, Yajin Chen, Yinmo Yang, Dianrong Xiu, Mao-Lin Yan, Xiaodong Wang, Quanli Han, Shunchang Jiao, Guang Tan, Jizhou Wang, Lianxin Liu, Jinghai Song, Jiajie Liao, Hong Zhao, Peng Li, Tianqiang Song, Zhanbo Wang, Jing Yuan, Bingyang Hu, Yufeng Yuan, Meng Zhang, Shuyang Sun, Jialin Zhang, Wentao Wang, Tianfu Wen, Jiayin Yang, Xilin Du, Tao Peng, Feng Xia, Zuojin Liu, Weibo Niu, Ping Liang, Jianming Xu, Xiao Zhao, Min Zhu
Abstract
Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the Healthy China 2030 blueprint, the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focused on the latest progress since the release of the Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) and resulted in a new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice, standardize medical care, and promote the development of the discipline.